Bemotrizinol: what the first new US sunscreen filter in 20 years adds

On June 9, 2026, the U.S. Food and Drug Administration announced that it was expanding the list of sunscreen active ingredients for the first time in 20 years [1]. The next day it issued Final Administrative Order OTC000039, which adds bemotrizinol, at concentrations up to 6 percent, to Over-the-Counter Monograph M020 for sunscreen drug products [2]. The order took effect on August 9, 2026 [2].

The ingredient itself is not new. Bemotrizinol, abbreviated BEMT and listed on ingredient panels as bis-ethylhexyloxyphenol methoxyphenyl triazine, is the oil-soluble triazine filter behind the trade names Tinosorb S and, in the US filing, Parsol Shield [4][8]. Sunscreens sold in Europe and other international markets have contained it for years [7]. What changed in 2026 is its legal status in the United States, and that change is worth describing precisely.

A final order is not a drug approval

Sunscreens in the US are regulated as over-the-counter drugs. Most are marketed under a monograph, a set of conditions under which an active ingredient is treated as generally recognized as safe and effective (GRASE) and a product can be sold without an individually approved application [2]. Since the 2020 CARES Act, a company can ask the FDA to change a monograph through an OTC Monograph Order Request (OMOR) [2][7].

That is the route bemotrizinol took. DSM Nutritional Products LLC submitted a Tier 1 OMOR on September 23, 2024; the FDA published a proposed order on December 12, 2025, took public comments, and issued the final order on June 10, 2026 [2]. Bemotrizinol was the first new sunscreen active ingredient to be evaluated under the FDA's GRASE testing expectations, which include a maximal usage trial of systemic absorption [3].

The wording matters because "FDA approved" implies a product-by-product review with an approved label. A monograph order instead sets conditions that any compliant product may meet. The FDA's own press language is that it "expanded sunscreen options" [1], and the commentary literature describes the event as a filter being added to the monograph [8][12].

What the final order allows

Two further points from the order are easy to miss. First, in response to a public comment, the FDA noted that bemotrizinol sunscreens, like every nonprescription topical drug, must be labeled "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away" [2]. Second, the order does not evaluate any finished product. It evaluates an ingredient under conditions; SPF, water resistance, and broad-spectrum labeling still depend on the formulation and its testing [2].

What the evidence behind the order shows

Efficacy

The FDA concluded that "two independent human clinical efficacy studies" provided adequate evidence that bemotrizinol at up to 6 percent works as a sunscreen active [2]. The final order summarizes that conclusion rather than reporting the studies' SPF values, and this article has not reviewed the underlying scientific review, so no efficacy number is quoted here.

What the published literature does support is the mechanism. Bemotrizinol absorbs across UVB and UVA and is inherently photostable, meaning it does not degrade quickly under the radiation it absorbs [4]. In laboratory work by filter-manufacturer scientists, it also stabilized a photolabile partner filter, ethylhexyl methoxycinnamate, mainly through an energy-quenching mechanism [5]. A 2026 physical-chemistry study attributes the molecule's stability and low reactive-oxygen generation to fast excited-state relaxation and a solvent-dependent absorption shift [13]. Those properties are why formulators value it, and why the commentary literature frames its US arrival as a formulation turning point rather than a marginal addition [8].

Absorption and systemic exposure

The FDA now expects a maximal usage trial (MUsT) for sunscreen actives, testing plasma levels after repeated application at high doses over large body areas [3][7]. The pilot MUsT for 6 percent bemotrizinol, published in 2023 by authors affiliated with DSM, found that plasma concentrations rarely exceeded the FDA's 0.5 ng/mL threshold, that there was no evidence of accumulation, and that adverse events were limited to one moderate and a few mild treatment-emergent events [3]. The FDA's final order states that the clinical pharmacology data showed bemotrizinol "is not readily absorbed through human skin, even with repeat application" [2].

An independent in-vitro study on porcine skin reached a compatible conclusion for four European filters including BEMT: none penetrated through the skin over 24 hours, most of each filter stayed on the surface (over 90 percent), and only a fraction reached the epidermis and dermis [6].

Local tolerability

The FDA wrote that the dermal studies showed "no instances of irritation, phototoxicity, or photoallergenicity" and that, together with the low absorption, this was why it did not require separate pediatric studies [2]. Postmarketing reports in children were "very few," and the types of adverse events reported were similar to those in adults [2].

Why a single filter matters

The US monograph has listed roughly ten UV filters, while Europe has more than 30 [3]. Reviews of the regulatory gap argue that several internationally used filters, bemotrizinol among them, offer broader and more stable protection than older US options and that the OMOR pathway is the realistic way to close the gap [7]. A 2026 correspondence in the Journal of the American Academy of Dermatology made the same comparison against the Korean filter list [9].

For patients this is less abstract than it sounds. The review literature argues that the newer international filters give broader and more stable UV protection than the older US set, and ties the case for them to skin cancer prevention, since ultraviolet radiation is the main environmental cause [7]. A photostable UVA-UVB filter that also steadies its neighbors gives formulators more room, which is the point the JAAD commentary makes [8]. A pediatric pharmacology commentary frames the same change in terms of children's photoprotection [12].

Our earlier article on summer photoprotection and visible light covered why tinted, iron-oxide formulations matter for melasma. Bemotrizinol does not change that advice; it changes what US manufacturers can build the UV side of a formula from.

Adverse events, limitations, and realistic expectations

• Contact allergy has been reported. Allergic contact dermatitis to bemotrizinol, confirmed by patch testing, has been described in case reports from Japan and France, with the 2024 report asking whether it is "an emerging allergen" [10][11]. Case reports do not give a frequency. They do mean that a new rash after switching to a bemotrizinol product deserves a dermatologist's attention rather than an assumption that a "new-generation" filter cannot be the cause.
• The central pharmacokinetic study is industry authored. The pilot MUsT was conducted and published by DSM-affiliated authors [3], and much of the photostability literature comes from filter manufacturers [4][5]. That is normal for a regulatory submission, and the FDA reviewed the data, but readers should weigh the source.
• Pediatric data are limited. The FDA said so directly while still including children from 6 months [2]. Public comments asked for postmarketing surveillance and noted the absence of data on bemotrizinol in human breast milk; the FDA agreed that surveillance matters but did not treat the breast-milk question as a safety gap [2].
• The order says nothing about a specific product's SPF. How well any sunscreen protects still depends on the whole formula, the labeled SPF and broad-spectrum test results, the amount applied, and reapplication. A better filter cannot compensate for applying a quarter of the tested dose.
• Availability is a market question. With 18 months of exclusivity for the requestor [2], the number of US products in the first year will depend on licensing decisions this article cannot verify. Check the Drug Facts panel rather than marketing claims.
• This does not make older filters unsafe. The order adds an option; it does not withdraw zinc oxide, titanium dioxide, or avobenzone. The FDA's separate questions about other organic filters remain a different regulatory track and are not addressed by this order [2][7].

Bottom line

Final Administrative Order OTC000039 added bemotrizinol, at up to 6 percent, to the US sunscreen monograph as generally recognized as safe and effective for adults and children 6 months and older, effective August 9, 2026 [2]. The FDA's decision rested on two clinical efficacy studies, a maximal usage trial showing minimal systemic absorption, and dermal studies without irritation, phototoxicity, or photoallergenicity [2][3].

The published literature supports the molecule's broad-spectrum, photostable profile and its ability to stabilize other filters [4][5][13]. The realistic caveats are contact allergy reported in case series [10][11], industry authorship of key data [3], limited pediatric data acknowledged by the FDA itself [2], and the ordinary truth that a filter is only as good as the formula and the application habit around it.

This article is for informational purposes and does not constitute medical advice. Questions about sunscreen selection for a specific skin condition, pregnancy, or a suspected reaction should be directed to a qualified clinician.